Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14538231 | 0.84 | NPC1 (0.66) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3199124 | 0.83 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1753828 | 0.82 | L3MBTL1 (0.71) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9492626 | 0.82 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL842631 | 0.82 | NPC1 (0.68) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12678025 | 0.81 | NPC1 (0.66) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11234425 | 0.81 | RAB9A (0.66) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18773997 | 0.80 | NPC1 (1.00) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21972887 | 0.80 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2668066 | 0.80 | NPC1 (0.61) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759824-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | QUANTUMDX GROUP LIMITED (GB) | 2020-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759824-B2 | Design, synthesis and use of synthetic nucleotides comprising charge mass tags | POLM, RNGTT, TYMP | NPC1 4771/4885RAB9A 2763/4885MEN1 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.